Patents by Inventor Adam Matthew Gilbert

Adam Matthew Gilbert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200262833
    Abstract: The present invention provides, in part, compounds of Formula I, or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: (R1)a, (R2)b, (R3)c, L, A, and E are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.
    Type: Application
    Filed: June 14, 2018
    Publication date: August 20, 2020
    Inventors: Elizabeth Mary Beck, Michael Aaron Brodney, Matthew Frank Brown, Christopher Ryan Butler, Adam Matthew Gilbert, Erik Alphie Lachapelle, Laura Ann McAllister, Daniel Paul Uccello, Lei Zhang
  • Patent number: 10723711
    Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, traumatic brain injury, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer.
    Type: Grant
    Filed: August 21, 2019
    Date of Patent: July 28, 2020
    Assignee: Pfizer Inc.
    Inventors: Christopher Ryan Butler, Laura Ann McAllister, Elizabeth Mary Beck, Michael Aaron Brodney, Adam Matthew Gilbert, Christopher John Helal, Douglas Scott Johnson, Justin Ian Montgomery, Steven Victor O'Neil, Bruce Nelsen Rogers, Patrick Robert Verhoest, Damien Webb
  • Patent number: 10703756
    Abstract: The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl, and pyrrolo[2,3-b]pyridinyl acrylamides, epoxides, and analogues thereof. Such compounds are useful for inhibiting Janus Kinase (JAK). This invention also is directed to compositions comprising methods for making such compounds, and methods for treating and preventing conditions mediated by JAK.
    Type: Grant
    Filed: April 19, 2016
    Date of Patent: July 7, 2020
    Assignee: Pfizer Inc.
    Inventors: Atli Thorarensen, Matthew Frank Brown, Agustin Casimiro-Garcia, Ye Che, Mark Edward Flanagan, Adam Matthew Gilbert, Matthew Merrill Hayward, Jean-Baptiste Telliez, Rayomand Jal Unwalla, John I. Trujillo, Sidney Xi Liang
  • Publication number: 20200207762
    Abstract: The present invention provides, in part, compounds of Formula I: or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: R1, R2, L, A, and E are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.
    Type: Application
    Filed: February 21, 2020
    Publication date: July 2, 2020
    Inventors: Lei Zhang, Christopher Ryan Butler, Elizabeth Mary Beck, Michael Aaron Brodney, Matthew Frank Brown, Laura Ann McAllister, Erik Alphie LaChapelle, Adam Matthew Gilbert
  • Patent number: 10604519
    Abstract: The present invention provides, in part, compounds of Formula I: or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: R1, R2, L, A, and E are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: March 31, 2020
    Assignee: Pfizer Inc.
    Inventors: Lei Zhang, Christopher Ryan Butler, Elizabeth Mary Beck, Michael Aaron Brodney, Matthew Frank Brown, Laura Ann McAllister, Erik Alphie LaChapelle, Adam Matthew Gilbert
  • Publication number: 20190382359
    Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, traumatic brain injury, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer.
    Type: Application
    Filed: August 21, 2019
    Publication date: December 19, 2019
    Applicant: PFIZER INC.
    Inventors: CHRISTOPHER RYAN BUTLER, LAURA ANN MCALLISTER, ELIZABETH MARY BECK, MICHAEL AARON BRODNEY, ADAM MATTHEW GILBERT, CHRISTOPHER JOHN HELAL, DOUGLAS SCOTT JOHNSON, JUSTIN IAN MONTGOMERY, STEVEN VICTOR O'NEIL, BRUCE NELSEN ROGERS, PATRICK ROBERT VERHOEST, DAMIEN WEBB
  • Patent number: 10428034
    Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, traumatic brain injury, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: October 1, 2019
    Assignee: Pfizer Inc.
    Inventors: Christopher Ryan Butler, Laura Ann McAllister, Elizabeth Mary Beck, Michael Aaron Brodney, Adam Matthew Gilbert, Christopher John Helal, Douglas Scott Johnson, Justin Ian Montgomery, Steven Victor O'Neil, Bruce Nelsen Rogers, Patrick Robert Verhoest, Damien Webb
  • Patent number: 10328082
    Abstract: The present invention relates to a compound of Formula 1, 2 or 3: wherein A is N or —CR0—, where R0 is hydrogen, C1-C6 linear or branched chain alkyl, etc., Z is —CRe—, or, —N—, where Re is hydrogen, C1-C6 linear or branched chain alkyl, etc.; R1 is hydrogen, C1-C6 linear or branched chain alkyl, etc.; R2 are independently hydrogen or C1-C6 linear or branched chain alkyl; R3 and R4 are independently hydrogen, C1-C6 linear or branched chain alkyl, etc.; R5 and R6 are independently hydrogen or C1-C6 linear or branched chain alkyl, etc.; R8 is hydrogen, C1-C6 linear or branched chain alkyl, etc.; R9 and R10 are independently hydrogen or C1-C6 linear or branched chain alkyl, etc.
    Type: Grant
    Filed: May 18, 2015
    Date of Patent: June 25, 2019
    Assignee: Pfizer Inc.
    Inventors: Eugene Lvovich Piatnitski Chekler, Adam Matthew Gilbert, Rayomand Jal Unwalla, Patrick Robert Verhoest, James Thomas Anderson
  • Publication number: 20190002466
    Abstract: The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl, and pyrrolo[2,3-b]pyridinyl acrylamides, epoxides, and analogues thereof. Such compounds are useful for inhibiting Janus Kinase (JAK). This invention also is directed to compositions comprising methods for making such compounds, and methods for treating and preventing conditions mediated by JAK.
    Type: Application
    Filed: April 19, 2016
    Publication date: January 3, 2019
    Applicant: Pfizer Inc.
    Inventors: Atli THORARENSEN, Matthew Frank BROWN, Agustin CASIMIRO-GARCIA, Ye CHE, Mark Edward FLANAGAN, Adam Matthew GILBERT, Matthew Merrill HAYWARD, Jean-Baptiste TELLIEZ, Rayomand Jal UNWALLA, John I. TRUJILLO, Sidney Xi LIANG
  • Publication number: 20180065943
    Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, traumatic brain injury, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer.
    Type: Application
    Filed: November 9, 2017
    Publication date: March 8, 2018
    Applicant: PFIZER INC.
    Inventors: CHRISTOPHER RYAN BUTLER, LAURA ANN MCALLISTER, ELIZABETH MARY BECK, MICHAEL AARON BRODNEY, ADAM MATTHEW GILBERT, CHRISTOPHER JOHN HELAL, DOUGLAS SCOTT JOHNSON, JUSTIN IAN MONTGOMERY, STEVEN VICTOR O'NEIL, BRUCE NELSEN ROGERS, PATRICK ROBERT VERHOEST, DAMIEN WEBB
  • Publication number: 20180002331
    Abstract: The present invention provides, in part, compounds of Formula I: or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: R1, R2, L, A, and E are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.
    Type: Application
    Filed: June 29, 2017
    Publication date: January 4, 2018
    Applicant: Pfizer Inc.
    Inventors: Lei Zhang, Christopher Ryan Butler, Elizabeth Mary Beck, Michael Aaron Brodney, Matthew Frank Brown, Laura Ann McAllister, Erik Alphie LaChapelle, Adam Matthew Gilbert
  • Patent number: 9845301
    Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, traumatic brain injury, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: December 19, 2017
    Assignee: PFIZER INC.
    Inventors: Christopher Ryan Butler, Laura Ann McAllister, Elizabeth Mary Beck, Michael Aaron Brodney, Adam Matthew Gilbert, Christopher John Helal, Douglas Scott Johnson, Justin Ian Montgomery, Steven Victor O'Neil, Bruce Nelsen Rogers, Patrick Robert Verhoest, Damien Webb
  • Publication number: 20170252352
    Abstract: The present invention relates to a compound of Formula 1, 2 or 3: I II III wherein A is N or —CR0—, where R0 is hydrogen, C1-C6 linear or branched chain alkyl, etc., Z is —CRe—, or, —N—, where Re is hydrogen, C1-C6 linear or branched chain alkyl, etc.; R1 is hydrogen, C1-C6 linear or branched chain alkyl, etc.; R2 are independently hydrogen or C1-C6 linear or branched chain alkyl; R3 and R4 are independently hydrogen, C1C6 linear or branched chain alkyl, etc.; R5 and R6 are independently hydrogen or C1-C6 linear or branched chain alkyl, etc.; R8 is hydrogen, C1-C6 linear or branched chain alkyl, etc.; R9 and R10 are independently hydrogen or C1-C6 linear or branched chain alkyl, etc.
    Type: Application
    Filed: May 18, 2015
    Publication date: September 7, 2017
    Applicant: Pfizer Inc.
    Inventors: Eugene Lvovich Piatnitski CHEKLER, Adam Matthew GILBERT, Rayomand Jal UNWALLA, Patrick Robert VERHOEST, James Thomas ANDERSON
  • Publication number: 20170247372
    Abstract: The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl and pyrrolo[2,3-d]pyridinyl acrylamides and analogues thereof. Such compounds are useful for inhibiting Janus Kinase (JAK). This invention also is directed to compositions comprising methods for making such compounds, and methods for treating and preventing conditions mediated by JAK.
    Type: Application
    Filed: March 1, 2017
    Publication date: August 31, 2017
    Applicant: Pfizer Inc.
    Inventors: Atli Thorarensen, Matthew Frank Brown, Agustin Casimiro-Garcia, Ye Che, Jotham Wadsworth Coe, Mark Edward Flanagan, Adam Matthew Gilbert, Matthew Merrill Hayward, Jonathan David Langille, Justin Ian Montgomery, Jean-Baptiste Telliez, Rayomand Jal Unwalla, John I. Trujillo
  • Patent number: 9617258
    Abstract: The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl and pyrrolo[2,3-d]pyridinyl acrylamides and analogues thereof, having the structure: or a pharmaceutically acceptable salt or solvate thereof, or an enantiomer or diastereomer thereof, as set forth in the Description. Such compounds are useful for inhibiting Janus Kinase (JAK). This invention also is directed to compositions comprising methods for making such compounds, and methods for treating and preventing conditions mediated by JAK.
    Type: Grant
    Filed: December 3, 2014
    Date of Patent: April 11, 2017
    Assignee: Pfizer Inc.
    Inventors: Atli Thorarensen, Matthew Frank Brown, Agustin Casimiro-Garcia, Ye Che, Jotham Wadsworth Coe, Mark Edward Flanagan, Adam Matthew Gilbert, Matthew Merrill Hayward, Jonathan David Langille, Justin Ian Montgomery, Jean-Baptiste Telliez, Rayomand Jal Unwalla, John I. Trujillo
  • Publication number: 20170029390
    Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, traumatic brain injury, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer.
    Type: Application
    Filed: July 28, 2016
    Publication date: February 2, 2017
    Applicant: PFIZER INC.
    Inventors: CHRISTOPHER RYAN BUTLER, LAURA ANN MCALLISTER, ELIZABETH MARY BECK, MICHAEL AARON BRODNEY, ADAM MATTHEW GILBERT, CHRISTOPHER JOHN HELAL, DOUGLAS SCOTT JOHNSON, JUSTIN IAN MONTGOMERY, STEVEN VICTOR O'NEIL, BRUCE NELSEN ROGERS, PATRICK ROBERT VERHOEST, DAMIEN WEBB
  • Patent number: 9328104
    Abstract: The present invention relates to a compound of Formula 1, 2 or 3: wherein A is N or —CR0—, where R0 is hydrogen, C1-C6 linear or branched chain alkyl, etc., Z is —CRe—, or, —N—, where Re is hydrogen, C1-C6 linear or branched chain alkyl, etc.; R1 is hydrogen, C1-C6 linear or branched chain alkyl, etc.; R2 are independently hydrogen or C1-C6 linear or branched chain alkyl; R3 and R4 are independently hydrogen, C1-C6 linear or branched chain alkyl, etc.; R5 and R6 are independently hydrogen or C1-C6 linear or branched chain alkyl, etc.; R8 is hydrogen, C1-C6 linear or branched chain alkyl, etc.; R9 and R10 are independently hydrogen or C1-C6 linear or branched chain alkyl, etc.
    Type: Grant
    Filed: December 2, 2013
    Date of Patent: May 3, 2016
    Assignee: Pfizer Inc.
    Inventors: James Thomas Anderson, Eugene Lvovich Piatnitski Chekler, Edmund L. Ellsworth, Bruce Kipp Erickson, Adam Matthew Gilbert, Anthony P. Ricketts, David P. Thompson, Rayomand Jal Unwalla, Patrick Robert Verhoest
  • Patent number: 9079915
    Abstract: The present invention relates to substituted thienyl- and furanyl-isoquinolinones that act, for example, as modulators of poly(ADP-ribose) polymerase (PARP). The present invention also relates to processes for the preparation of substituted thienyl and furanyl-isoquinolinones and to their use in treating various diseases and disorders.
    Type: Grant
    Filed: December 13, 2013
    Date of Patent: July 14, 2015
    Inventors: Roberto Pellicciari, Flavio Moroni, Eric Christian Hansen, Adam Matthew Gilbert, Peter John Larkin
  • Publication number: 20150158864
    Abstract: The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl and pyrrolo[2,3-d]pyridinyl acrylamides and analogues thereof. Such compounds are useful for inhibiting Janus Kinase (JAK). This invention also is directed to compositions comprising methods for making such compounds, and methods for treating and preventing conditions mediated by JAK.
    Type: Application
    Filed: December 3, 2014
    Publication date: June 11, 2015
    Inventors: Atli Thorarensen, Matthew Frank Brown, Agustin Casimiro-Garcia, Ye Che, Jotham Wadsworth Coe, Mark Edward Flanagan, Adam Matthew Gilbert, Matthew Merrill Hayward, Jonathan David Langille, Justin Ian Montgomery, Jean-Baptiste Telliez, Rayomand Jal Unwalla
  • Publication number: 20140155390
    Abstract: The present invention relates to a compound of Formula 1, 2 or 3: wherein A is N or —CR0—, where R0 is hydrogen, C1-C6 linear or branched chain alkyl, etc., Z is —CRe—, or, —N—, where Re is hydrogen, C1-C6 linear or branched chain alkyl,etc.; R1 is hydrogen, C1-C6 linear or branched chain alkyl, etc.; R2 are independently hydrogen or C1-C6 linear or branched chain alkyl; R3 and R4 are independently hydrogen, C1-C6 linear or branched chain alkyl, etc.;. R5 and R6 are independently hydrogen or C1-C6 linear or branched chain alkyl, etc.; R8 is hydrogen, C1-C6 linear or branched chain alkyl, etc.; R9 and R10 are independently hydrogen or C1-C6 linear or branched chain alkyl, etc.
    Type: Application
    Filed: December 2, 2013
    Publication date: June 5, 2014
    Applicant: Pfizer Inc.
    Inventors: James Thomas Anderson, Eugene Lvovich Piatnitski Chekler, Edmund L. Ellsworth, Bruce Kipp Erickson, Adam Matthew Gilbert, Anthony P. Ricketts, David P. Thompson, Rayomand Jal Unwalla, Patrick Robert Verhoest